

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19

Title: Sensitive extraction-free SARS-CoV-2 RNA virus detection using a novel RNA preparation method

Authors: Bin Guan¹, Karen M. Frank², José O. Maldonado^{3,4}, Margaret Beach⁴, Eileen Pelayo⁴, Blake M. Warner⁴, Robert B. Hufnagel¹

Affiliation and address:

¹Ophthalmic Genetics and Visual Function Branch, National Eye Institute,
²Department of Laboratory Medicine, Clinical Center,
³AAV Biology Section, National Institute of Dental and Craniofacial Research,
⁴Salivary Disorders Unit, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, 20892, USA.

Number of text pages, tables and figures: No. of text pages, 11; tables, 1; figures: 5 (plus 4 supplementary figures)

Short running head: Extraction-free SARS-CoV-2 RNA detection

Grant numbers and sources of support: Intramural Research Programs of the National Institutes of Health (Clinical Center, NEI, NIDCR)

Corresponding author: Robert B. Hufnagel, Ophthalmic Genomics Laboratory, National Eye Institute, National Institutes of Health, 10 Center Drive, Building 10, Rm 10N109, Bethesda, MD, 20892, USA.
Phone: 301-503-1305. Email: robert.hufnagel@nih.gov

1 **Abstract**

2 Current conventional detection of SARS-CoV-2 involves collection of a patient sample with a
3 nasopharyngeal swab, storage of the swab during transport in a viral transport medium, extraction of
4 RNA, and quantitative reverse transcription PCR (RT-qPCR). We developed a simplified and novel
5 preparation method using a Chelex resin that obviates RNA extraction during viral testing. Direct
6 detection RT-qPCR and digital-droplet PCR was compared to the current conventional method with RNA
7 extraction for simulated samples and patient specimens. The heat-treatment in the presence of Chelex
8 markedly improved detection sensitivity as compared to heat alone, and lack of RNA extraction shortens
9 the overall diagnostic workflow. Furthermore, the initial sample heating step inactivates SARS-CoV-2
10 infectivity, thus improving workflow safety. This fast RNA preparation and detection method is versatile for
11 a variety of samples, safe for testing personnel, and suitable for standard clinical collection and testing on
12 high throughput platforms.

1 Introduction

2 Diagnostic testing for SARS-CoV-2 is crucial to combatting the current COVID-19 pandemic, even as
3 vaccines are being distributed. The Centers for Disease Control and Prevention (CDC) protocol for
4 detecting SARS-CoV-2 (COVID-19) involves sample collection, RNA extraction, and one-step real-time
5 reverse transcription PCR (rRT-PCR or RT-qPCR) (accessed on 6/15/2020:
6 <https://www.fda.gov/media/134922/download>). Uncontrolled community spread of SARS-CoV-2 has
7 caused supply shortages for diagnostic tests, including the RNA extraction kits. Supply chain uncertainty
8 and lack of adequate supplies remain widespread which hinders day-to-day laboratory operations and
9 impedes efforts to increase testing capacity (survey results published on Nov. 9, 2020 and accessed on
10 11/12/2020: <https://asm.org/Articles/2020/September/Clinical-Microbiology-Supply-Shortage-Collecti-1>).

11 Recent research aimed at both simplifying current standard testing procedures for SARS-CoV-2
12 and alleviating RNA extraction kit shortage have shown encouraging results. First, specimens collected
13 on nasopharyngeal swabs (NP swab) have been eluted into low-ethylenediaminetetraacetic acid (EDTA)
14 tris buffer (lowTE) and directly used for one-step RT-qPCR without RNA extraction. This results in lower
15 threshold cycles (Ct values).¹ The lower Ct value suggests that eliminating the RNA extraction step may
16 increase sensitivity. Secondly, samples collected in viral transport medium (VTM) have been successfully
17 used for direct RT-qPCR detection after heating.²⁻¹⁰ Despite these noteworthy results, the Ct values were
18 4 or more cycles higher than the standard protocol utilizing the RNA extraction step. A lower inherent
19 detection sensitivity leads to higher false negative rate, which is a particular risk for low viral load
20 samples.^{2, 5, 10} Thirdly, proteinase K and heat has been used for NP and oropharyngeal swabs with 91%
21 sensitivity, albeit with higher Ct than the conventional RNA extraction method in the RT-qPCR assays.¹¹
22 ¹² Recently, saliva samples with RNA extraction have been found to be an effective alternative sample
23 type to NP swabs.¹²⁻¹⁴ Further studies showed that the SalivaDirect® method, employing proteinase K
24 and heat-treatment, were able to detect 6 genome-copies per µl of SARS-CoV-2 without RNA
25 extraction.¹⁵ While RNA extraction-free methods are promising, they lack the sensitivity and limit of
26 detection compared to the current CDC protocol.

1 In this study, we aimed to improve the reported RNA extraction-free protocols to match or exceed
2 the sensitivity to that of the standard protocol with RNA-extraction using both synthetic and human
3 samples. We tested a variety of common chemicals that are used in molecular biology laboratories, and
4 tested different preparation methods to identify reagents and conditions that (i) minimize RNA
5 degradation, (ii) allow room temperature transport, heat inactivation, and storage of human samples, and
6 (iii) provide sensitive RNA detection by RT-qPCR or RT-ddPCR. We found that Chelex[®] 100, a chelating
7 ion exchange resin, preserves essentially all SARS-CoV-2 RNA in the sample and permits direct
8 detection by both RT-qPCR and RT-ddPCR. We further demonstrated a COVID-19 testing workflow that
9 obviate the use of a BSL-2 hood and omitting RNA-extraction while preserving the sensitivity of the
10 standard protocol with RNA-extraction.

11 **Results**

12 Heating in lowTE buffer along with Chelex detects all virion RNA added

13 Given the promising results for COVID-19 testing obtained by direct elution of dried patient swab to lowTE
14 (1x low-EDTA TE, 10 mM Tris, 0.1mM EDTA, pH8.0) buffer,¹ and because heating has been shown to
15 increase testing sensitivity for SARS-CoV-2 when samples stored in viral transport media (VTM) were
16 used for direct testing without RNA extraction,^{2, 5, 10} we set out to test these conditions in a direct dried
17 swab elution procedure. We simulated the dry swab procedure by desiccating the mixture of inactivated
18 SARS-CoV-2 virions with known genome copies and 293FT cells using a speedvac centrifuge at room
19 temperature. After resuspending the virus and cells in lowTE to a concentration of 1,000 genome
20 copies/ μ l, we quantified the virus with RT-ddPCR using the N1 and N2 primers and showed that only
21 ~30% of virions were detected (Figure 1A, dried swab, no heat). Heating increased the detected virus to
22 ~40% of added virions (Figure 1A, dried swab, heat).

23 As RNases are Mg²⁺-dependent similar to DNases, and Chelex polymers have been used
24 successfully for DNA preparation for its property of chelating divalent ions,¹⁶ we tested viral RNA isolation
25 using Chelex. Heating the sample along with 5% Chelex improved virion detection to ~50% (Figure 1A,
26 dried swab, Heat_Chelex). We suspected that the desiccation-resuspension process caused viral and

1 cellular RNA degradation. To confirm this, we added virions and 293FT cells directly to lowTE and
2 measured viral RNA content (Figure 1A, wet swab). Heating the sample in lowTE in the presence of
3 Chelex led to the detection of ~100% of virions added. The *RPP30* mRNA also had the highest yield in
4 the presence of Chelex. Heating without Chelex led to more *RPP30* mRNA degradation but better
5 detection of the SARS-CoV-2 RNA as compared to no heat condition. The N1, N2 primers produced
6 minimum background as shown in the controls (lowTE and 293FT cells suspended in lowTE) (Figure 1B).

7 The pH of 5% Chelex in water is 10-11.¹⁶ Because alkaline conditions are expected to lead to
8 rapid RNA hydrolysis, we postulated that Tris pH8.0 in the lowTE buffer was critical for the high detection
9 rate of SARS-CoV-2 virions in the presence of Chelex. To test this, we measured detectable virion RNA
10 when samples were prepared in water (Figure 1C). In water, heating with Chelex only detected 20% of
11 added virions, and 15% of the *RPP30* mRNA detected in the lowTE/Chelex condition. We also simulated
12 swab stored in MEM α media, which has a similar formulation to VTM. Heating in MEM α led to an
13 undetectable level of viral RNA and *RPP30* mRNA, possibly due to the 1.8 mM Ca^{2+} and 0.8 mM Mg^{2+}
14 present in the media. Inclusion of Chelex during heating resulted in detection of >55% of viral RNA
15 (Figure 1C). We found that inclusion of 2.5-5% DMSO in the final ddPCR reaction reduced negative
16 droplets intensity (Supplementary Figure 1), we also simulated swab stored in the TED10 (90% lowTE +
17 10% DMSO) buffer, which results in 2.5% DMSO in the ddPCR reaction and thus potentially simplifies
18 reaction setup. The viral and *RPP30* RNA amounts detected in the TED10 buffer in Chelex was slightly
19 higher than those in lowTE buffer.

20 The CDC recommends VTM for specimens for viral culture and viral detection, which contains
21 HBSS 1X with calcium and magnesium, 2% heat-inactivated FBS, Gentamicin and Amphotericin B (CDC
22 SOP# DSR-052-05 accessed on 11/16/2020, [https://www.cdc.gov/coronavirus/2019-](https://www.cdc.gov/coronavirus/2019-ncov/downloads/Viral-Transport-Medium.pdf)
23 [ncov/downloads/Viral-Transport-Medium.pdf](https://www.cdc.gov/coronavirus/2019-ncov/downloads/Viral-Transport-Medium.pdf)). The 1X HBSS buffer contains 1.3 mM Ca^{2+} and 0.9 mM
24 Mg^{2+} , which may lead to viral RNA degradation during heating, similar to MEM α medium. We tested the
25 HBSS buffer without $\text{Ca}^{2+}/\text{Mg}^{2+}$ but supplemented with 2% heat-inactivated FBS, HBSS buffer containing
26 $\text{Ca}^{2+}/\text{Mg}^{2+}$ and 2% heat-inactivated FBS, the M4 transport medium (HBSS based medium, containing
27 HEPES, BSA, gelatin, and antibiotics), and PBS in the RNA-extraction free assay (Figure 1D). Heat

1 increased viral detection for calcium/magnesium free media, but not the calcium/magnesium media. Only
2 ~12% of viral RNA was detected in the HBSS containing $\text{Ca}^{2+}/\text{Mg}^{2+}$ and 2% heat-inactivated FBS after
3 heating, in contrast, heating in the presence of Chelex allowed the detection of 84% of virions.

4 In summary, LowTE pH 8.0 and TED10 with Chelex produced the highest amounts of viral RNA
5 detected as compared to no heat or heating conditions among the buffers tested.

6 Buffers allowing successful RT-qPCR without conventional RNA extraction

7 To investigate whether other agents besides Chelex could similarly be used for efficient RNA extraction-
8 free SARS-CoV-2 detection by protecting against degradation, we tested various buffers for RT-qPCR
9 without conventional RNA extraction. These buffers included RNA later (used for sample storage before
10 RNA extraction), buffer RLT (lysis buffer from the Qiagen RNeasy RNA extraction kit), Urea (used for
11 RNA extraction¹⁷), DMSO (used as lysis buffer for DNA extraction¹⁸ and known to inhibit RNases¹⁹), 1xTE
12 (10 mM Tris, 1 mM EDTA, pH8.0), 10xTE (20mM Tris, 10 mM EDTA, pH7.5), and MEM α medium.
13 Inactivated SARS-CoV-2 and 293FT cells were mixed and added to these buffers above along with
14 lowTE and heated with or without Chelex (Figure S2A). We diluted the samples in water before RT-qPCR
15 to avoid suspected inhibition of reverse transcription and PCR, and then compared the Ct values to
16 calculated Ct values based on Ct of extracted RNA and number of virions present in each sample.

17 Of the chemicals tested, RNA later and RLT appeared to be incompatible with the RNA-extraction-
18 free method, as there was either no amplification or the Ct values were much higher than expected for all
19 four targets (Figure S2A) after 20-fold dilution. Urea, DMSO, TE or MEM α showed minimum RT-qPCR
20 inhibition after dilutions. Chelex appears critical to achieve better detection of viral RNA and cellular RNA
21 in DMSO, 1xTE, lowTE, or MEM α , with the average Ct cycle difference of N1 & N2 between Chelex and
22 heat alone as 2.2, 1.8, 1.4, and 13, respectively. This represents improvement of sensitivity by Chelex of
23 4.5, 3.6, 2.7, and >1000 fold for samples prepared in DMSO, 1xTE, lowTE and MEM α , respectively. In
24 summary, viral RNA detection sensitivity in simulated nasopharyngeal swab samples was highest in the
25 presence of Chelex.

1 Next, we tested saliva samples with known added virion concentrations. Inactivated SARS-CoV-
2 2 virions were also added to saliva, which were then mixed 1:1 with various buffers as above, to test
3 whether saliva samples can be subjected to direct RNA detection. Saliva samples without exogenous
4 chemicals or in DMSO were superior for RT-qPCR detection among the tested conditions (Figure S2A).
5 Chelex 5% did not improve Ct for saliva, while decreased 3.4 Ct cycles for saliva 1:1 mixed with DMSO
6 (Figure S2A).

7 We then determined the maximum concentrations of tested chemicals that were tolerated in a
8 RT-qPCR reaction (Figure S2B). Samples were heat-treated with Chelex and serial dilutions of 2-fold
9 were used for RT-qPCR. The highest chemical concentrations that did not interfere with RT-qPCR if using
10 5 µl of undiluted sample in a 20 µl reaction were Urea 0.5 M, DMSO 50%, EDTA 0.5 mM (Figure S2B).
11 The N1 & N2 Ct values for the undiluted sample in lowTE was the lowest, lower than RNA-extraction
12 using the same amount of virions, likely reflecting RNA loss during RNA extraction.

13 Together these results indicate that, by obviating the RNA extraction step, the presence of Chelex
14 in sample buffer increases RNA molecules available for RT-qPCR, as we observed in a variety of buffers
15 simulating nasopharyngeal and saliva collection conditions. Collecting swabs in lowTE appear to provide
16 the highest sensitivity under synthetic conditions.

17 Limit of detection

18 We attempted to further refine the buffer for this RNA-extraction free method by adjusting DMSO
19 concentration and combining TE with DMSO. The RT-qPCR data showed that lowTE with heat and
20 Chelex showed the lowest Ct values for N1 and N2, and combination of TE with DMSO did not improve
21 the Ct (Figure S3A). Among the saliva samples, the undiluted saliva condition had the lowest Ct for N1
22 and N2 (Figure S3A), with Ct values ~0.5 cycles above the lowTE sample. Heated saliva samples with or
23 without Chelex lowered Ct values by more than 2 cycles compared to non-heated samples. We further
24 found that increasing Chelex levels in DMSO increased detectable viral and cellular RNA (Figure S3B).

25 To improve the limit of detection for RT-qPCR, we optimized the reaction conditions by (i)
26 including 2.5% DMSO in the final reaction if a sample does not contain DMSO, (ii) reducing the reaction

1 volume to 10 μ l, (iii) using the NEB-Luna-program II for RT-qPCR, reducing denaturing time from 10
2 seconds to 5 seconds and annealing/extension time from 40 seconds to 20 seconds (Figure S4). Under
3 this condition, the Ct for Non-template controls were either undetermined or above 38. When analyzing
4 the 10-fold serial dilutions of SARS-CoV-2 virions using our new preparation method by RT-qPCR, the
5 LoD was 200 copies per swab or 1 copy/ μ l of samples before RT-qPCR (Figure 2A). Using the
6 conventional RNA extraction method, the LoD was 2,000 genome copies per swab (Figure 2A). The LoD
7 for saliva samples using the Chelex method was also at 1 copy/ μ l for all replicates when 50 μ l whole
8 unstimulated saliva was added to 25 μ l of 50% Chelex, compared to the proteinase K method, which was
9 undetermined for a single 1 copy/ μ l replicate (Figure 2B).

10 We then used RT-ddPCR to determine whether we could detect a lower virion copy number.
11 Because we occasionally observed 1 or 2 positive droplets in the no-template control reactions, we
12 applied 1.8 copies/ μ l, or 50% higher than the maximum N1/N2 mean of negative controls (Figure 1B and
13 Figure 2C), for the mean of N1 and N2 as the threshold for being positive for the SARS-CoV-2 N1/N2 RT-
14 ddPCR assay. RT-ddPCR confirmed the LoD for conventional RNA extraction method to 2,000 virions per
15 swab and the lowTE-Heat-Chelex method to 200 virions per swab (Figure 2C and Table 1). The RNA
16 extraction method only detected 30-50% of RNA molecules at the viral loads tested (Table 1).

17 In summary, the lower limit of detection of the Chelex method is 1 copy/ μ l in NP or saliva under
18 optimized buffer conditions and it avoids virion loss as observed in RNA extraction protocols.

19 Patient samples

20 We then validated our Chelex RNA preparation method using primary patient samples. NP swabs were
21 collected in M4 (N=14, S01 to S14, Figure 3A) or PBS (N=2, S15 & S16). These samples were tested in
22 the NIH Clinical Center diagnostic laboratory using conventional CDC RNA extraction and RT-qPCR
23 method (easyMAG-CL method), then frozen. Three of these samples, S01 to S03, had viral titer above
24 200 genome copies/ μ l. Twelve samples had viral titer less than 20 genome copies/ μ l, including eight
25 considered indeterminate because only one of N1 or N2 targets was positive. One sample, S14, was
26 negative.

1 Samples were thawed and mixed with the Chelex resin, heat-inactivated, and subjected to RT-
2 qPCR using the NEB Luna RT-qPCR kit (Chelex-Luna method). As the easyMAG-CL method enriched
3 sample 4-fold before RT-qPCR, we expected that Ct values from the Chelex-Luna method would increase
4 by 2-fold including loss that may occur during RNA extraction (50% detectable viral materials in M4 in the
5 Chelex-Luna assay; Figure 1D). The Ct values for N1, N2, and RPP30 from clinical laboratory RT-qPCR
6 and NEB Luna RT-qPCR were comparable when using a common set of purified patient RNA samples
7 with different viral titer (data not shown). The mean difference of N1 Ct between the two methods was
8 2.7, excluding four samples (S10, S11, S12, and S16) that did not show a Ct value in the Chelex-Luna
9 assay.

10 Of the twelve samples with less than 20 genome copies/ μ l, eight (or 67%) showed as positive in
11 the N1 Chelex-Luna assay, including two samples (S13 and S15) that showed lower Ct values and
12 another (S08) with the similar Ct value. The N2 Ct values were higher than N1 and many were higher
13 than 38, thus were not informative for the low titer samples in the Chelex-Luna assay. Two NP swab
14 samples stored in the CDC-suggested VTM (HBSS with Calcium & Magnesium, S17 and S18) were
15 tested side-by-side using the easyMag-CL and Chelex-Luna methods. The N1 & N2 Ct values of both
16 samples increased 2 and 4, respectively, reflecting likely inhibition by the VTM as observed in the
17 synthetic samples (Figure 3A).

18 Next, we compared the RNA extraction and Chelex methods using two primary saliva samples
19 (Saliva01 & 02) and 20 positive saliva samples diluted in negative saliva samples side-by-side (Saliva03
20 to 22, Figure 3B). The mean Ct differences between the Chelex and RNA extraction methods for N1 and
21 N2 were 1.6 and 2.6 respectively. Among the six samples with less than 10 genome copies/ μ l as
22 determined by the RNA extraction method, five showed as positive and one (Saliva20) was indeterminate
23 in the Chelex assay (Figure 3B). Thus, the Chelex method demonstrated similar sensitivity as the RNA
24 extraction method for both primary NP swab and saliva samples.

25 We then tested the optimized Chelex RNA isolation method prospectively by collecting
26 symptomatic patient NP swabs (n = 7) and saliva-saturated swabs (n = 4) directly into 0.5 ml (NP) or 0.4
27 ml (saliva) Chelex containing buffer, side-by-side with swabs collected into 3 ml VTM. The Chelex

1 samples were heated and used for NEB Luna RT-qPCR, and the samples in VTM were subjected to RNA
2 extraction followed by RT-qPCR performed at the clinical laboratory. Because 1/6th of buffer in the
3 collection tube was used in the Chelex method and RNA extraction concentrated sample by 4-fold, the Ct
4 values in the Chelex method are expected to be 0.6 lower than the RNA extraction method. Sample P1
5 was found to be negative using both methods, and five of the six NP samples and four of the four saliva
6 samples had lower N1 and N2 Ct values in the Chelex method as compared to the RNA extraction
7 method (Figure 3C). The NP sample N1 Ct differences for patients P2 to P7 between these two methods
8 were -1.9, -2.1, -4.2, 0.8, -3.2, and -6.4, and their N2 Ct differences were -0.3, -5.5, -6.1, -0.7, -3.2, and -
9 9.7. The saliva samples' N1 Ct differences for patients P4 to P7 between these two methods were -1.1, -
10 2.1, -2.5, and -1.1, and their N2 Ct differences were -5.6, -3.9, -3.7, and -7.2. Thus, the Chelex method
11 may offer better sensitivities using the procedure here. In addition, the Chelex method allowed sample
12 processing without a Biosafety Cabinet hood as the samples were inactivated before tube opening.

13 Sample stability at room temperature

14 We then determined whether viral and cellular RNA were stable over time. Samples were stored at room
15 temperature then heat-treated in the presence of Chelex and assayed at different timepoints as indicated
16 (Figure 4). Viral RNAs in lowTE or TED10 were relatively stable at room temperature and ~80% of N1 or
17 N2 RNAs were detected on day 5 (Figure 4A). Viral RNAs were less stable in MEM α medium as > 80%
18 were degraded after 3 days (Figure 4A). The cellular RNA was less stable than viral RNA in the similar
19 conditions (Figure 4A). We then determined the RNA stability at room temperature after heat-treatment
20 with Chelex (Figure 4B). Heat-treatment stabilized both viral and cellular RNA, and >80% viral RNAs
21 and >60% cellular RNA were detected on day 5 (Figure 4B).

22 A similar stability experiment was performed for virions prepared in saliva samples. The viral
23 RNAs were stable in saliva before heat-treatment, as a higher amount of viral RNAs were detected after
24 storage at room temperature, possibly because interfering agents in saliva degrade during storage
25 (Figure 5A). However, the viral RNA stability decreased markedly after heat treatment (Figure 5B).

26

1 Discussion

2 Our novel preparation approach using Chelex polymer increased RNA yield available for RT-
3 qPCR and RT-ddPCR detection compared to the conventional method using the simulated samples with
4 the ATCC SARS-CoV-2 virions. When using stored patient samples, RNA extraction provided higher
5 sensitivity (Figure 3A, B). This is likely due to the enrichment arising from the lower volume of RNA eluate
6 as compared to the input sample volume. The lower sensitivity of the Chelex method seen in Figure 3A
7 could be also due to RNA loss during the freeze-thaw cycle. When the samples were tested side-by-side
8 (Figure 3B), the sensitivities of the Chelex method and RNA extraction method are comparable. When
9 patient samples were collected in VTM (S17 & S18 in Figure 3A), the N1 and N2 Ct values increased 2
10 and 4, respectively, suggesting that the Chelex method on VTM-collected samples may result in lower
11 sensitivity for some low viral load samples. Further, we found that N1 and N2 responded differently
12 toward components in the VTM as the N1 Ct increased while N2 Ct decreased after 1:2 dilution (S19 &
13 S20 in Figure 3A). Our results in Figure 3C showed that collecting the swab directly in Chelex-TED
14 (TE+DMSO) buffers followed by heating provided the best sensitivity for SARS-CoV-2 detection. The
15 higher LoD associated with conventional RNA extraction method was due to dilution in the VTM and loss
16 of RNA during RNA extraction as shown in Table 1. In addition, viral RNA may be degraded faster when
17 storing in the calcium/magnesium containing VTM, as suggested by data presented in Figure 4A. As
18 such, we recommend primary sample collection for this RNA isolation method in either TED or lowTE
19 buffer, which has similar or better detection performance as RNA extraction methods for primary samples
20 collected in VTM.

21 We also demonstrate that the Chelex method allows for highly-reproducible detection of 1
22 genome copy/ μ l of the SARS-CoV-2 virions, a 6-15-fold improvement in detection sensitivity.^{15, 20} One
23 explanation for this improvement is that the Chelex resin chelates the divalent ions necessary for Rnase
24 activities, and the resin may be able to non-specifically remove inhibitors to reverse-transcription and/or
25 PCR. In addition, un-processed samples may lead to more RNA degradation during sample collection
26 and storage as compared to being stored in the presence of Chelex. We further identified conditions that
27 allow sensitive detection of SARS-CoV-2 in saliva. The potential benefits of saliva testing include lower

1 cost (no swab), reduced variability, and improved patient acceptance over traditional NP swab.^{14, 21} Thus,
2 the Chelex method may provide a more sensitive point-of-care method for RNA diagnostics by reducing
3 false negative results.

4 There will be a continued need for SARS-CoV-2 detection during and after the current vaccination
5 period. The sheer volume of preprint and publications in a short period of time illustrates the urgent need
6 and hope to increase testing capacity employing the RNA-extraction free approach. The utility of this RNA
7 isolation method for both NP and saliva samples would increase the number of people tested in the same
8 timeframe as the current method. In addition to improved sensitivity, this method offers a number of
9 additional advantages compared to the current gold standard clinical laboratory testing, including
10 improved cost, reduced sample processing time and complexity, and enhanced workflow safety. The cost
11 of CDC-recommended VTM collection tube is ~\$1.70 per tube, and RNA extraction may cost > \$6 per
12 sample. We estimate the total cost of Chelex, lowTE, DMSO, and the collection tube is <\$1 per sample.
13 Thus, the Chelex method will save cost and reduce supply chain burden by eliminating the need for RNA
14 extraction and VTM. The novel RNA preparation method, amenable for high-throughput processing, is
15 expected to shorten diagnostic testing time by omitting the RNA extraction step and omitting the chemical
16 disinfection of patient samples. This method utilizes a heat-inactivation step that minimizes viral RNA
17 loss, obviates the need for a biological safety cabinet, and eliminates exposure of laboratory personnel to
18 live virus. Therefore, we fully expect that this method will facilitate broader availability and testing capacity
19 for not only, COVID-19, but also for other infectious pathogens. Because of the observed stability of
20 SARS-CoV-2 RNA in collected samples at room temperature, this method should also improve access to
21 COVID-19 testing in resource scarce regions of the world, by improving RNA stability, reducing cost of
22 collection kits and diagnostic reagents, and eliminating the requirement of refrigeration, biosafety cabinet,
23 and storage of RNA extraction kits.

24 Because the Chelex method also allowed cellular RNA detection, we expect that the method
25 could find wide use in both clinical and research laboratories. DNA present in the solution is not expected
26 to interfere with many applications because RT-qPCR can be performed using exon-spanning primers
27 and polyA selection is often an integrated step in RNAseq. The DNA present may be also used as a

1 normalization control since the DNA content reflects the cell number when two cell populations have
2 similar percentages of cells in the G2/M phases. This helps alleviate the concerns of choosing a proper
3 house-keeping gene during RNA expression analysis.²² If DNA needs to be removed before downstream
4 application, Dnase I treatment may be performed using commercially available Dnase I kits. The new
5 RNA preparation method could also be used together with other RNA detection method such as rolling
6 circle amplification, loop-mediated isothermal amplification or SHERLOCK.²³⁻²⁵

7 One limitation of the current study was the low-level contamination observed in the RT-ddPCR
8 assay, where one or two positive droplets were observed in the no-template control reactions. The
9 contamination could result from either viral RNA or PCR amplicon present in the research laboratory. Due
10 to the background contamination, we used 1.8 copies/ μ l as the low limit of detection for the SARS-CoV-2
11 N1/N2 RT-ddPCR assay. According to the FDA Emergency Use Authorization (EUA) by the manufacturer
12 Bio-Rad, the low limit of detection in the 1-well RT-ddPCR assay system is 2 positive droplets and no
13 positive droplets observed in no-template controls. Thus the low limit of detection in a RT-ddPCR assay
14 could reach 0.1 copy/ μ l if performing in a clean room.

15 In summary, we robustly demonstrate improvements in COVID-19 viral testing workflow using
16 synthetic and real-world samples employing the Chelex-based extraction-free workflow. This methodology
17 has the clear benefit of dramatic improvements in sensitivity, cost, and time savings for clinical laboratory
18 testing. Additionally, this method exhibits improved safety characteristics including obviating the need for
19 the use of a biological safety cabinet and harsh disinfection chemicals prior to testing. Finally, this method
20 is easily adapted to both clinical and research laboratories and could be standard of care for nucleic acid
21 testing and transport in the near future.

22

23 **Online Methods**

24 Human samples

1 Samples were collected from healthy volunteers and subjects who provided informed consent to National
2 Institutes of Health (NIH) Institutional Review Board (IRB)-approved protocols (20-D-0094,
3 NCT04348240; 20-CC-0128, NCT04424446) at the NIH Clinical Center.

4 Sample collection

5 We used four types of samples for assay development and validation: (i) simulated samples containing
6 the heat-inactivated SARS-CoV-2 virions obtained from ATCC (VR-1986HK, concentration measured by
7 ddPCR at ATCC); (ii) positive patient saliva samples diluted into negative saliva samples; (iii) historical
8 patient samples including nasopharyngeal swab and whole unstimulated saliva; and (iv) prospective
9 paired nasopharyngeal and saliva samples swabs. The paired NP and saliva samples were collected at
10 the NIH Symptomatic Testing Facility. Briefly, a FLOQswab® (COPAN) was inserted into the nares and
11 advanced posteriorly to the nasopharynx as previously described.²⁶ Swabs were then inserted into VTM.
12 Subjects were asked to expectorate into a sterile 50 mL conical vial every 30 seconds for 3-5 minutes, or
13 until ~3 mL of saliva was collected. A FLOQswab® was inserted into the saliva and immediately
14 transferred into VTM. Samples were placed on ice and shipped immediately to the NIH Clinical Center
15 Clinical Laboratory for standard CDC testing. In parallel, NP samples were placed in 0.5 ml 10% Chelex
16 in TED10 buffer (90% lowTE and 10% DMSO), and swabs with saliva were placed in 0.4 ml Chelex saliva
17 buffer. The 0.4 ml Chelex saliva buffer was made by mixing 0.2 ml of 50% Chelex in TED99 and 0.2 ml of
18 lowTE. TED99 was 10mM Tris pH8.0, 0.1mM EDTA and 99% DMSO, which was made by mixing 100 µl
19 of 1 M Tris pH8.0, 2 µl of 0.5 M EDTA, and 9.9 ml of DMSO. These patient samples with Chelex in 15-ml
20 tubes were heat-inactivated in a thermomixer for 10 min at 98 °C before testing.

21 Clinical laboratory CDC SARS-CoV-2 Assay

22 The conventional RNA-extraction RT-qPCR method following CDC guideline has been reported, and
23 herein referred as easyMAG-CL (clinical laboratory) assay.²¹ Briefly, nucleic acid from individual
24 specimens was extracted from 200 µL of Saliva/NPspecimens using the NucliSENS® easyMAG® platform
25 (bioMérieux, Marcy l'Etoile, France) with an elution volume of 50 µL. 5 µl RNA was then used for RT-
26 qPCR in 20 µl reaction volume. PCR was performed on the ABI 7500 Fast Real-Time PCR System

1 (Thermo Fisher Scientific, Waltham, MA). The assay utilized primer/probe sets for nucleocapsid protein,
2 2019-nCoV_N1 and 2019-nCoV_N2, and the human RNase P (*RPP30* gene, also referred as *RP* gene in
3 the CDC protocol) as an internal control to ensure that extraction and amplification was adequate as
4 described. Cycle threshold (Ct) values were recorded for N1, N2 and RNase P for each sample. Samples
5 were considered positive for SARS-CoV-2 when both N1 and N2 targets were detected with Ct count <40.
6 The positive signal for N1 or N2 alone was defined as an indeterminate result.

7 Chemicals, buffers, and cells

8 Chelex® 100 Resin (hereafter “Chelex”; cat# 142-1253, molecular biology grade) was obtained from Bio-
9 Rad. Molecular biology grade water (cat# 351-029-101), TE pH 8.0 (cat# 351-011-131), 1M Tris-HCl
10 pH7.5 (cat# 351-006-101), HBSS with Ca²⁺/Mg²⁺ (cat# 114-061-101) were from Quality Biological
11 (Gaithersburg, MD). The low-EDTA TE or lowTE buffer (10 mM Tris, pH8.0, 0.1 mM EDTA, cat# 12090-
12 015), Urea (cat# 15505-050), RNAlater (cat# AM7024), MEM medium (cat# 12571-063), HBSS without
13 Ca²⁺/Mg²⁺ (cat# 14175-095), M4 (cat# R12550), heat-inactivated FBS, 293FT cells were procured from
14 Thermo Fisher Scientific. Dimethyl sulfoxide (DMSO, cat# D2650-100ML) was from Sigma. 1M Tris-HCl
15 pH8.0 (cat#221-232) and 0.5M EDTA (cat#221-057) were from Crystalgen (Commack, NY). PBS (cat#
16 RGF-3190, pH7.2) was from KD Medical (Columbia, MD). TED10 buffer was 90% lowTE and 10% DMSO
17 (volume to volume).

18 Chelex was first prepared in H₂O, lowTE, or TED99 at 50% (50 grams/100 ml total volume, or
19 500 milligrams Chelex to 550 µl H₂O). The 50% Chelex was then added in 1/10 volume to samples to
20 obtain 5% Chelex in a PCR strip with a wide-bore tip. The samples were vortexed briefly then heated in a
21 PCR cycler for 5 min at 98 °C, followed by spinning at 1,000 to 2,000xg for 2 mins in a swing-rotor. The
22 supernatant was then used for RT-qPCR or -ddPCR.

23 For simulated samples involving the ATCC virions, the RNeasy mini kit (Qiagen) was used to
24 extract RNA from virion and cell mixture of less than 10 µl that contained the expected amounts of virions.
25 The RNeasy Protect Saliva Mini Kit (Qiagen) was used for RNA extraction from ATCC virion-simulated
26 saliva samples.

1 Primers, RT-qPCR and RT-ddPCR

2 The primer and probe sequences used for detecting SARS-CoV-2 and human *RPP30* targets in the RT-
3 ddPCR and NEB Luna RT-qPCR were identical to the easyMAG-CL assay above. The *RPP30* (or RP)
4 primers and probe in the CDC protocol, whose sequences are RPP30F AGATTTGGACCTGCGAGCG,
5 RPP30R GAGCGGCTGTCTCCACAAGT, RPP30Hex TTCTGACCTGAAGGCTCTGCGCG, amplify the
6 DNA sequence located in the exon 1 of the *RPP30* gene, thus are expected to amplify both cDNA and
7 genomic DNA contents. An additional *RPP30* primer specific for *RPP30* cDNA was designed to span the
8 exon 1 and exon 2, RPP30cR GCAACAACCTGAATAGCCAagGT, where the lower case “ag” denotes the
9 exon junction. RPP30cR was used for RT-qPCR or -ddPCR together with RPP30F and RPP30Hex. The
10 primer and probe sequences for an ultra-conserved region in chromosome 5 are: chr5UC-F
11 ATTTATGACCAGCCACAGCC, chr5UC-R CCATCAGGGACTTGGTTTCA, chr5UC-Hex
12 CAACTCCAGCAGCTGCACACCGC. Primers and probes were ordered from Eurofins Genomics or
13 IDTDNA.

14 The Luna Universal Probe One-Step RT-qPCR Kit (#E3006X, NEB) was used for RT-qPCR with
15 the following cycling conditions using a QuantStudio 3 real-time PCR system (ThermoFisher Scientific):
16 NEB-Luna-Program I: 55°C for 10 min, 95°C for 1 min, and 45 cycles of 95 °C for 10 sec and 60 °C for 40
17 sec or NEB-Luna-Program II: 55°C for 10 min, 95°C for 1 min, and 45 cycles of 95 °C for 5 sec and 60 °C
18 for 20 sec. Ct (Crossing threshold) values for N1 & N2 (viral targets) were set at 0.1 Δ Rn, Ct values for
19 cRPP30 (specific for *RPP30* cDNA) and RPP30 (targets both genomic DNA and cDNA) were at 0.02
20 Δ Rn. The N1 and N2 Ct of less than 38 were considered positive in the NEB Luna RT-qPCR assay.

21 The 1-Step RT-ddPCR Advanced Kit for Probes (#186-4021, Bio-Rad) was used for RT-ddPCR
22 using the QX200 Droplet Digital PCR System (Bio-Rad). The cycling condition for RT-ddPCR was: 50°C
23 for 60 min, 95°C for 10 min, and 40 cycles of 94°C for 10 sec and 55°C for 60 sec, followed by 98°C for
24 10 min, 4°C for 30 min then hold at 4°C. If DMSO was not present in the sample, DMSO was added to
25 2.5% in the RT-qPCR or -ddPCR reaction, unless specified otherwise.

26

1 **Acknowledgments**

2 This work was supported by the Intramural Research Programs of the National Institutes of Health
3 (Clinical Center, NEI, NIDCR). The content of this publication does not necessarily reflect the views or
4 policies of the Department of Health and Human Services, nor does mention of trade names, commercial
5 products, or organizations imply endorsement by the U.S. Government. We would like to acknowledge
6 staff in the National Institutes of Health Department of Laboratory Medicine, Occupational Medical
7 Services COVID-19 Testing Facility, and the Division of Fire and Rescue Services.

8

9 **Author contributions**

10 B.G., K.M.F., B.M.W. and R.B.H. designed experiments and wrote the manuscript. K.M.F., J.O.M., M.B.,
11 E.P., and B.M.W. collected patient samples. All authors contributed to the manuscript editing.

12

13 **Competing interests**

14 NEI (B.G. and R.B.H.) filed an invention disclosure. NEI has protected the intellectual property around this
15 technology which is available for licensing and co-development. Please contact
16 neitechtransfer@nei.nih.gov for more information.

17

1 References

- 2 1. Srivatsan, S. et al. Preliminary support for a “dry swab, extraction free” protocol for SARS-CoV-2
3 testing via RT-qPCR. *bioRxiv*, 2020.2004.2022.056283 (2020).
- 4 2. Beltrán-Pavez, C. et al. SARS-CoV-2 detection from nasopharyngeal swab samples without RNA
5 extraction. *bioRxiv*, 2020.2003.2028.013508 (2020).
- 6 3. Grant, P.R., Turner, M.A., Shin, G.Y., Nastouli, E. & Levett, L.J. Extraction-free COVID-19 (SARS-
7 CoV-2) diagnosis by RT-PCR to increase capacity for national testing programmes during a
8 pandemic. *bioRxiv* (2020).
- 9 4. Lubke, N. et al. Extraction-free SARS-CoV-2 detection by rapid RT-qPCR universal for all primary
10 respiratory materials. *J Clin Virol* **130**, 104579 (2020).
- 11 5. Bruce, E.A. et al. Direct RT-qPCR detection of SARS-CoV-2 RNA from patient nasopharyngeal
12 swabs without an RNA extraction step. *PLoS Biol* **18**, e3000896 (2020).
- 13 6. Hasan, M.R. et al. Detection of SARS-CoV-2 RNA by direct RT-qPCR on nasopharyngeal
14 specimens without extraction of viral RNA. *PLoS One* **15**, e0236564 (2020).
- 15 7. Alcoba-Florez, J. et al. Fast SARS-CoV-2 detection by RT-qPCR in preheated nasopharyngeal swab
16 samples. *Int J Infect Dis* **97**, 66-68 (2020).
- 17 8. Merindol, N. et al. SARS-CoV-2 detection by direct rRT-PCR without RNA extraction. *J Clin Virol*
18 **128**, 104423 (2020).
- 19 9. Smyrlaki, I. et al. Massive and rapid COVID-19 testing is feasible by extraction-free SARS-CoV-2
20 RT-PCR. *Nat Commun* **11**, 4812 (2020).
- 21 10. Fomsgaard, A.S. & Rosenstjerne, M.W. An alternative workflow for molecular detection of SARS-
22 CoV-2 - escape from the NA extraction kit-shortage, Copenhagen, Denmark, March 2020. *Euro*
23 *Surveill* **25** (2020).

- 1 11. Mallmann, L. et al. Pre-treatment of the clinical sample with Proteinase K allows detection of
2 SARS-CoV-2 in the absence of RNA extraction. *bioRxiv* (2020).
- 3 12. Chu, A.W. et al. Evaluation of simple nucleic acid extraction methods for the detection of SARS-
4 CoV-2 in nasopharyngeal and saliva specimens during global shortage of extraction kits. *J Clin*
5 *Viro* **129**, 104519 (2020).
- 6 13. Sakanashi, D. et al. Comparative evaluation of nasopharyngeal swab and saliva specimens for
7 the molecular detection of SARS-CoV-2 RNA in Japanese patients with COVID-19. *J Infect*
8 *Chemother* (2020).
- 9 14. Wyllie, A.L. et al. Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2. *N Engl*
10 *J Med* **383**, 1283-1286 (2020).
- 11 15. Vogels, C.B.F. et al. SalivaDirect: A simplified and flexible platform to enhance SARS-CoV-2
12 testing capacity. *medRxiv* (2020).
- 13 16. Walsh, P.S., Metzger, D.A. & Higuchi, R. Chelex 100 as a medium for simple extraction of DNA for
14 PCR-based typing from forensic material. *Biotechniques* **10**, 506-513 (1991).
- 15 17. Almarza, J., Morales, S., Rincon, L. & Brito, F. Urea as the only inactivator of RNase for extraction
16 of total RNA from plant and animal tissues. *Anal Biochem* **358**, 143-145 (2006).
- 17 18. Campo, E.M.d., Hoyo, A.d., Casano, L.M., Martínez-Alberola, F. & Barreno, E. A rapid and cost-
18 efficient DMSO-based method for isolating DNA from cultured lichen photobionts. *Taxon* **59**,
19 588-591 (2010).
- 20 19. Moreno, J.M., Sinisterra, J.V. & Ballesteros, A. Influence of Organic Aqueous-Media in the Rnase
21 Activity of Spleen Phosphodiesterase. *J Mol Catal* **62**, 341-351 (1990).
- 22 20. Mancini, F. et al. Laboratory management for SARS-CoV-2 detection: a user-friendly
23 combination of the heat treatment approach and rt-Real-time PCR testing. *Emerg Microbes*
24 *Infect* **9**, 1393-1396 (2020).

- 1 21. Barat, B. et al. Pooled Saliva Specimens for SARS-CoV-2 Testing. *J Clin Microbiol* (2020).
- 2 22. Panina, Y., Germond, A., Masui, S. & Watanabe, T.M. Validation of Common Housekeeping
3 Genes as Reference for qPCR Gene Expression Analysis During iPS Reprogramming Process. *Sci*
4 *Rep* **8**, 8716 (2018).
- 5 23. Kellner, M.J., Koob, J.G., Gootenberg, J.S., Abudayyeh, O.O. & Zhang, F. SHERLOCK: nucleic acid
6 detection with CRISPR nucleases. *Nat Protoc* **14**, 2986-3012 (2019).
- 7 24. Park, G.S. et al. Development of Reverse Transcription Loop-Mediated Isothermal Amplification
8 Assays Targeting Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). *J Mol Diagn*
9 **22**, 729-735 (2020).
- 10 25. Takahashi, H. et al. RNase H-assisted RNA-primed rolling circle amplification for targeted RNA
11 sequence detection. *Sci Rep* **8**, 7770 (2018).
- 12 26. Huang, N. et al. Integrated Single-Cell Atlases Reveal an Oral SARS-CoV-2 Infection and
13 Transmission Axis. *medRxiv* (2020).

14

1 **Table**

2 Table 1. Limit of Detection comparing conventional RNA extraction and new preparation method

"Swab" viral load (genome copies)	RNA-extraction			lowTE_Heat_Chelex		
	Theoretical virus concentration* (copies/μl)	Mean of N1/N2 concentration (copies/μl)	Percentage detected	Theoretical virus concentration* (copies/μl)	Mean of N1/N2 concentration (copies/μl)	Percentage detected
200k	266.7	86.8	33%	1000	976	98%
20k	26.7	12.0	45%	100	106	106%
2k	2.7	2.2	Detectable [#]	10	13.4	134%
200	0.3	0.5	ND [#]	1	2.1	Detectable [#]

3 *: Virus concentration in samples used for RT-ddPCR if there is no loss during sample processing.

4 #: ND, not detectable. The low limit of quantification in the 1-well RT-ddPCR assay is 4 copies/μl of a
 5 molecule. The means of N1 and N2 copy numbers for the control samples without virions added were
 6 less than 1.2 copies/μl, thus, we applied 1.8 copies/μl as the low limit of detection for the SARS-CoV-2
 7 N1/N2 RT-ddPCR assay.

1 **Figure Legends**

2 **Figure 1.** RT-ddPCR assays for simulated dry- and wet-swab using RNA-extraction free
3 methods for SARS-CoV-2 detection. **(A)** 200,000 SARS-CoV-2 virions and 20,000 293FT cells
4 were dried at room temperature in a speedvac and then resuspended in 200 μ l lowTE buffer to mimic the
5 dry swab. The same amount of virions and 293FT cells directly added to 200 μ l lowTE buffer was used to
6 mimic the wet swab. The samples expected to have 1000 virion genome copies/ μ l were then used directly
7 for RT-ddPCR (No Heat), heated at 98 $^{\circ}$ C for 5 min (Heat), or heated with 5% Chelex (Heat_Chelex). The
8 RT-ddPCR reactions were carried out in one well for N1 and cRPP30 and another well for N2 and
9 RPP30. **(B)** Negative controls and virion samples prepared as wet swab. The mean genome copies/ μ l of
10 N1 & N2 were less than 1.2 in negative controls without virions added. N1 & N2 target SARS-CoV-2.
11 cRPP30 is specific for *RPP30* cDNA, and RPP30 targets both genomic DNA and cDNA. Copies/ μ l refers
12 to concentration in the samples used for RT-ddPCR. The error bars represent Poisson 95% confidence
13 intervals. Dashed line indicates the threshold for the low detection limit of 1.8 copies/ μ l of SARS-CoV-2
14 virions. **(C)** Virions of 1000 genome copies/ μ l and 100 293FT cells/ μ l were prepared in lowTE, H₂O, MEM
15 alpha, or TED10, treated and assayed by RT-ddPCR as in (A). **(D)** Virions of 1000 genome copies/ μ l and
16 100 293FT cells/ μ l were prepared in HBSS with or without Ca²⁺ & Mg²⁺ supplemented with 2% FBS, M4,
17 or PBS, treated and assayed by RT-ddPCR in for N1, N2, cRPP30 and chr5UC, a genomic DNA region
18 on chromosome 5.

19 **Figure 2.** The limit of detection of SARS-CoV-2 using RT-qPCR or -ddPCR. **(A)** RT-qPCR
20 comparing Chelex-RNA and conventional RNA extraction. RNA refers to RNA prepared by simulating
21 conventional method with RNA-extraction: a swab with 200,000 to 200 genome copies of SARS-CoV-2
22 virions was added to 3 ml of VTM, of which 200 μ l were used for RNA extraction, and RNA was eluted in
23 50 μ l H₂O. LowTE refers to simulating a swab with 200,000 to 200 genome copies of virions eluted in 200
24 μ l lowTE, and then heated in the presence of 5% Chelex. **(B)** RT-qPCR comparing Chelex and
25 Proteinase K methods for saliva samples. 1000 to 1 genome copies/ μ l of SARS-CoV-2 virions were
26 prepared in saliva samples and subjected to the Chelex or Proteinase K methods and RT-qPCR. The
27 NEB Luna RT-qPCR kit and NEB-Luna-Program II was used with 2.5 μ l samples in 10 μ l reaction volume.

1 Samples with undetermined Ct values were plotted as Ct 40. **(C)** The limit of detection of SARS-CoV-2
2 using RT-ddPCR. Samples from (A) were used for RT-ddPCR. 5 μ l of sample was used for RT-ddPCR in
3 20 μ l reaction volume. The mean genome copies/ μ l of N1 & N2 were less than 1.2 in negative controls
4 without virions added. N1 & N2 target SARS-CoV-2. cRPP30 is specific for *RPP30* cDNA, and RPP30
5 targets both genomic DNA and cDNA. Copies/ μ l refers to concentration in the samples used for RT-
6 ddPCR. The error bars represent Poisson 95% confidence intervals. Dashed line indicates the threshold
7 for the low detection limit of 1.8 copies/ μ l of SARS-CoV-2 virions. NTC, no-template control.

8 **Figure 3.** SARS-CoV-2 detection of patient samples prepared by the Chelex method.

9 **(A)** Patient NP swab samples were heated in the presence of 5% Chelex (S01 to S16, and S19, S20) or
10 10% Chelex (S17 & S18). S19 & S20 are 1:2 dilution of S17 & S18 in LowTE, respectively. **(B)** 50 μ l of
11 patient saliva samples (Saliva01 & 02) or negative patient saliva samples spiked with positive patient
12 saliva samples (Saliva03 to 22) were mixed with 25 μ l of 50% Chelex in TED99, and heated for 5 min in a
13 ThermoMixer. **(C)** Paired NP swabs from seven patients (P1 to P7) and saliva-saturated swabs from four
14 patients (P4 to P7) were collected in VTM or Chelex collection tubes. VTM samples were used for RNA
15 extraction (EasyMag). Luna refers to the NEB Luna RT-qPCR kit and NEB-Luna-Program II with 2.5 μ l
16 samples in a 10 μ l reaction volume. CL refers to CDC assay performed in the clinical laboratory with 5 μ l
17 samples in a 20 μ l reaction volume. Undetermined Ct values were plotted as Ct 40.

18 **Figure 4.** Viral and cellular RNA stability in lowTE by RT-ddPCR assays. **(A)** Virions of
19 1000 virion genome copies/ μ l and 100 cells/ μ l 293FT cells were prepared in lowTE, TED10 or MEM α ,
20 and stored at room temperature. Samples were heated with 5% Chelex on the time points indicated and
21 assayed. The RT-ddPCR reactions were carried out in one well for N1 and cRPP30 and another well for
22 N2 and RPP30. **(B)** Virions of 1000 virion genome copies/ μ l and 100 cells/ μ l 293FT cells were prepared
23 in the buffers, heated with 5% Chelex on day 0, and assayed on a time series. Copies/ μ l refers to
24 concentration in the samples used for RT-ddPCR. The error bars represent Poisson 95% confidence
25 intervals.

26 **Figure 5.** Viral RT stability in saliva by RT-ddPCR assays. **(A)** Virions were added to saliva
27 samples at 1000 virion genome copies/ μ l and stored at room temperature. Samples were heated with 1/5

1 volumes of 50% Chelex prepared in H₂O or TED99 on the time points indicated and assayed. The RT-
2 ddPCR reactions were carried out in one well for N1 and cRPP30 and another well for N2 and RPP30.
3 **(B)** Virions of 1000 virion genome copies/μl were prepared in saliva as in (A), heated with Chelex on day
4 0 or day 3, and assayed on the days indicated. cRPP30 data points were not plotted because of the low
5 level detected. Copies/μl refers to concentration in the samples used for RT-ddPCR. The error bars
6 represent Poisson 95% confidence intervals.

7 **Figure S1.** DMSO decreases negative droplet intensity in RT-ddPCR assays. The RT-
8 ddPCR reactions containing 0%, 2.5%, or 5% DMSO were performed for a Chelex-lowTE sample
9 prepared with the ATCC SARS-CoV-2 virions and 293FT cells using N1 and cRPP30 (left panel) or N2
10 and RPP30 (right panel). The grey clusters represent negative droplets; blue and green clusters
11 represent Fam and Hex positive droplets, respectively; and orange clusters represent double positive
12 droplets.

13 **Figure S2.** SARS-CoV-2 prepared in different buffers used for RT-qPCR without RNA-
14 extraction. **(A)** Samples were diluted in H₂O as indicated at the bottom. Expected_Ct refers to Ct
15 calculated based on Ct from extracted RNA normalized with added virion numbers after dilution using the
16 ΔCt method. **(B)** Buffer compatibility in RT-qPCR. Sample RNA, not heated and 5 μl of which contained
17 materials extracted from 6,250 virions. Other samples were heated in the presence of Chelex, of which
18 undiluted samples also contained 6,250 virions per 5 μl. Samples were diluted in H₂O. Samples with
19 undetermined Ct values were plotted as Ct 40. The NEB Luna RT-qPCR kit and NEB-Luna-Program I
20 was used. NTC, no-template control.

21 **Figure S3.** Tris EDTA and DMSO containing buffers. **(A)** RT-qPCR of samples with heat-
22 inactivated ATCC SARS-CoV-2 virions. 5 μl of samples were used for one reaction in RT-qPCR except
23 that samples in MEM α were diluted 1:1 with H₂O. Samples with undetermined Ct values were plotted as
24 Ct 40. The NEB Luna RT-qPCR kit and NEB-Luna-Program I was used. **(B)** RT-ddPCR of saliva samples
25 with heat-inactivated ATCC SARS-CoV-2 virions. The Chelex was prepared in H₂O, lowTE or TED99

1 (lowTE with 99% DMSO). RNA-kit refers to RNA extracted with the RNeasy Protect Saliva Mini Kit. NTC,
2 no-template control.

3 **Figure S4.** Optimization of the NEB Luna RT-qPCR assay. Extracted RNA samples were
4 serial diluted and assayed either using 2.5 μ l sample in a 10 reaction volume or 5 μ l in a 20 μ l reaction,
5 and using a longer PCR protocol (I: 10 seconds of denature and 40 seconds of annealing/extension) or a
6 shorter PCR protocol (II: 5 seconds of denature and 20 seconds of annealing/extension). NTC, no-
7 template control.




Figure 1

Figure 2

A



B



C







Figure 3

Figure 4





Figure 5

A



B




Figure S1






Figure S2

A



B





Figure S3

A



B




Figure S4

